Scholarlink

Background <p>Cyclosporine (CsA) is a calcineurin inhibitor (CNI) commonly prescribed after organ transplantation to reduce the risk of graft rejection and prolong both graft and patient survival. However, its clinical use is often limited by a narrow therapeutic index and highly variable, unpredictable pharmacokinetics. Consequently, close therapeutic monitoring is essential to ensure effective immunosuppression. Genetic polymorphisms in cytochrome P450 3&#xa0;A (CYP3A) enzymes and the multidrug resistance gene 1 (ABCB1) may influence CsA dose requirements and blood concentrations in renal transplant recipients.</p> Methods and results <p>This study aimed to evaluate the impact of selected single nucleotide polymorphisms (SNPs) in CYP3A4, CYP3A5, and ABCB1 genes in a cohort of Algerian renal transplant patients. Fifty stable kidney transplant recipients were enrolled. SNPs of CYP3A4, CYP3A5 and ABCB1 genes were detected with direct sequencing and associations between genotypes and CsA dose requirements, trough concentrations (C₀), 2&#xa0;h post dose concentration (C<sub>2</sub>) and dose-adjusted trough levels (C/D) were investigated. A significant decrease of CsA trough concentration C<sub>0</sub> and C<sub>0</sub>/D ratio was observed in the carriers of the heterozygote genotype <i>CYP3A5*1/3</i> against homozygote ones <i>CYP3A5</i>3/*3 (43.86 ± 16.53 vs. 58.21 ± 24.31 ng/mL per mg per kg); <i>p</i> = 0.039. Moreover, the <i>CYP3A5</i> *1/<i>3</i> genotype was associated with significantly lower cholesterol levels compared to patients carrying the <i>CYP3A5</i>3/*3 genotype (14.20 ± 10.66 vs. 33.11 ± 20.69); <i>p</i> = 0.0002. In contrast, the <i>ABCB1 3435&#xa0;C &gt; T</i> polymorphism (C/C, C/T, or T/T genotypes) showed no significant association with CsA pharmacokinetics.</p> Conclusions <p>In conclusion, the CYP3A5 A6986G (*3/*3) polymorphism is significantly associated with higher CsA trough levels and dose-adjusted concentrations, as well as increased cholesterol levels in stable renal transplant recipients even with similar doses. Conversely, variability in CsA pharmacokinetics does not appear to be significantly influenced by ABCB1 3435&#xa0;C &gt; T polymorphisms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The effect of CYP3A4, CYP3A5 and MDR1 (ABCB1) single nucleotide polymorphisms on the pharmacokinetics of cyclosporine in Algerian stable renal transplant recipients

  • 期刊论文

  • 发表日期：

    2025年7月25日

查看全文
  • Maya Bouafia,
  • Mohamed El Amine Smaali,
  • Souheila Zemmouchi,
  • Ali Boumegoura,
  • Selwa Bellara,
  • Ayomide Victor Atoki,
  • Raid Serrar,
  • Khalid Bouhedjar,
  • Mohammed Messaoudi,
  • Noureddine Abadi,
  • Mohamed Habib Belmahi

摘要

Background

Cyclosporine (CsA) is a calcineurin inhibitor (CNI) commonly prescribed after organ transplantation to reduce the risk of graft rejection and prolong both graft and patient survival. However, its clinical use is often limited by a narrow therapeutic index and highly variable, unpredictable pharmacokinetics. Consequently, close therapeutic monitoring is essential to ensure effective immunosuppression. Genetic polymorphisms in cytochrome P450 3 A (CYP3A) enzymes and the multidrug resistance gene 1 (ABCB1) may influence CsA dose requirements and blood concentrations in renal transplant recipients.

Methods and results

This study aimed to evaluate the impact of selected single nucleotide polymorphisms (SNPs) in CYP3A4, CYP3A5, and ABCB1 genes in a cohort of Algerian renal transplant patients. Fifty stable kidney transplant recipients were enrolled. SNPs of CYP3A4, CYP3A5 and ABCB1 genes were detected with direct sequencing and associations between genotypes and CsA dose requirements, trough concentrations (C₀), 2 h post dose concentration (C2) and dose-adjusted trough levels (C/D) were investigated. A significant decrease of CsA trough concentration C0 and C0/D ratio was observed in the carriers of the heterozygote genotype CYP3A5*1/3 against homozygote ones CYP3A53/*3 (43.86 ± 16.53 vs. 58.21 ± 24.31 ng/mL per mg per kg); p = 0.039. Moreover, the CYP3A5 *1/3 genotype was associated with significantly lower cholesterol levels compared to patients carrying the CYP3A53/*3 genotype (14.20 ± 10.66 vs. 33.11 ± 20.69); p = 0.0002. In contrast, the ABCB1 3435 C > T polymorphism (C/C, C/T, or T/T genotypes) showed no significant association with CsA pharmacokinetics.

Conclusions

In conclusion, the CYP3A5 A6986G (*3/*3) polymorphism is significantly associated with higher CsA trough levels and dose-adjusted concentrations, as well as increased cholesterol levels in stable renal transplant recipients even with similar doses. Conversely, variability in CsA pharmacokinetics does not appear to be significantly influenced by ABCB1 3435 C > T polymorphisms.